A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in
 participants with Type 1 diabetes mellitus (T1D) and impaired awareness of hypoglycemia (IAH)
 and severe hypoglycemia.
Key Inclusion Criteria:

 -  Clinical history of T1D with > 5 years of duration

 -  At least two episodes of documented severe hypoglycemia in the 12 months prior to
 enrollment

 -  Stable diabetic treatment

 -  Consistent use of continuous glucose monitor (CGM) for at least 3 months before
 Screening and willingness to use CGM for the duration of the study

 Key Exclusion Criteria:

 -  Prior islet cell transplant, organ transplant, or cell therapy

 Other protocol defined Inclusion/Exclusion criteria may apply